Continuous intrathecal administration of 5-fluoro-2′-deoxyuridine for the treatment of neoplastic meningitis

Neurosurgery

Volumn 57, Issue 2, 2005, Pages 266-279

  Nakagawa, Hidemitsu ^a   Miyahara, Eiji ^a   Suzuki, Tsuyoshi ^a   Wada, Kohichi ^a   Tamura, Masakazu ^a   Fukushima, Yuji ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

5 Fluoro 2 deoxyuridine; Intrathecal chemotherapy; Neoplastic meningitis

Indexed keywords

CISPLATIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NIMUSTINE; PACLITAXEL; UFT; VINDESINE;

ADULT; AGED; AORTA BALLOON; ARTICLE; BACTERIAL MENINGITIS; BRAIN RADIATION; BRAIN TUMOR; BRAIN VENTRICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CRANIAL NERVE; EDEMA; FEMALE; HEADACHE; HUMAN; MAINTENANCE THERAPY; MALE; MENINGITIS; MOTOR DYSFUNCTION; NAUSEA; NEOPLASTIC MENINGITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SENSORY DYSFUNCTION; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN NEOPLASMS; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; FLOXURIDINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 23244464104     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000166543.45294.F6     Document Type: Article

References (36)

1. Adamson PC, Balis FM, Arndt CA, Holcenberg JS, Narang PK, Murphy RF, Gillespie AJ, Poplack DG: Intrathecal 6-mercaptopurine: Preclinical pharmacology, phase I/II trial and pharmacokinetic study. Cancer Res 51:6079-6083, 1991.
2. Arita N, Ushio Y, Hayakawa T, Nagatani M, Huang TY, Izumoto S, Mogami H: Intrathecal ACNU: A new therapeutic approach against malignant leptomeningeal tumors. J Neurooncol 6:221-226, 1988.
3. Aur RJ, Hustu HO, Verzosa MS, Wood A, Simone JV: Comparison of two methods of preventing central nervous system leukemia. Blood 42:349-357, 1973.
4. Berg SL, Balis FM, Zimm S, Murphy RF, Holcenberg J, Sato J, Reaman G, Steinherz P, Gillespie A, Doherty K: Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 10:143-148, 1992.
5. Blaney SM, Poplack DG: New cytotoxic drugs for intrathecal administration. J Neurooncol 38:219-223, 1998.
6. Blaney SM, Heideman R, Berg S, Adamson P, Gillepie A, Geyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM: Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21:143-147, 2003.
7. Boogerd W, Hart AA, Van der Sande JJ, Engelsman E: Meningeal carcinomatosis in breast cancer: Prognostic factors and influence of treatment. Cancer 67:1685-1695, 1991.
8. 131I-radiolabelled monoclonal antibodies: Results of responses and long term follow-up in 40 patients. J Neurooncol 38:225-232, 1998.
9. Cokgor I, Friedman AH, Friedman HS: Current options for the treatment of neoplastic meningitis. J Neurooncol 60:79-88, 2002.
10. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI: Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 97:3053-3060, 2003.
11. Freilich RJ, Seidman AD, DeAngelis LM: Central nervous system progression of metastaric breast cancer in patients treated with paclitaxel. Cancer 76:232-236, 1995.
12. Gagliano R, Costani J: Paraplegia following intrathecal methotrexate: Report a case and review of the literature. Cancer 37:1663-1668, 1976.
13. Giannone L, Giannone L, Greco FA, Hainsworth JD: Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 4:68-73, 1986.
14. Glantz MJ, Cole BF, Recht L, Akerley W, Mills S, Saris S, Hochberg F, Calabresi P, Egorin MJ: High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 16:1561-1567, 1998.
15. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollete S, Schumann GB, Cole BF, Howell SB: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394-3402, 1999.
16. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11:561-569, 1993.
17. Hitchins RN, Bell DR, Woods RL, Levi JA: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:1655-1662, 1987.
18. Hrushesky WJ, Bjanason GA, Fukushima M, Hagimoto H: Identification of therapeutic plasma FUDR concentration during continuous infusion of individually determined maximum tolerated doses. Cancer Ther 2:50-57, 1999.
19. Kim S, Khatibi S, Howell SB, McCully C, Balis FM, Poplack DG: Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 53:1596-1598, 1993.
20. Laske DW, Muraszko KM, Oldfield EH, DeVroom HL, Sung C, Dedrick RL, Simon TR, Colandrea J, Copeland C, Katz D, Greenfield L, Groves ES, Houston LL, Youle RJ: Intraventricular immunotoxin for leptomeningeal neoplasia. Neurosurgery 41:1039-1051, 1997.
21. Nakagawa H, Fujita T, Kubo S, Izumoto S, Nakajima Y, Tsuruzono K, Tokiyoshi K, Hayakawa T: Ventriculolumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal carcinomatosis: A pilot study in 13 patients. Surg Neurol 45:256-264, 1996.
22. Nakagawa H, Fukushima Y, Tamura M, Yoshioka K, Itho K: Intrathecal or intracavitary administration of sodium butyrate to treat neoplastic meningitis and malignant glioma. Presented at the 95th Annual Meeting of American Association for Cancer Research, Orlando, Florida, March 27-31, 2004.
23. Nakagawa H, Maeda N, Tsuzuki T, Suzuki T, Hirayama A, Miyahara E, Wada K: Intracavitary chemotherapy with 5-fluoro-2′-deoxyuridine (FdUrd) in malignant brain tumors. Jpn J Clin Oncol 31:251-258, 2001.
24. Nakagawa H, Yamada M, Fukushima M, Ikenaka K: Intrathecal 5-fluoro-2′-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: An in vivo study. Cancer Chemother Pharmacol 43:247-256, 1998.
25. Nakagawa H, Yamada M, Maeda M, Iwatsuki K, Hirayama A, Ikenaka K: Clinical trial of intrathecal administration of 5-fluoro-2′-deoxyuridine for treatment of meningeal dissemination of malignant tumors. J Neurooncol 45:175-183, 1999.
26. Noell WK, Magoss MS, Cohen LH, Holland JF, Walters GC: Cerebral effects of folic acid, pyrimidines, amino acids and their antimetabolites. Electroencephalogr Clin Neurophysiol 12:238, 1960.
27. Nugent JL, Bunn PA Jr, Matthews MJ, Ihide DC, Cohen MH, Gazdar A, Minna JD: CNS metastases in small cell bronchogenic carcinoma: Increasing frequency and changing pattern with lengthening survival. Cancer 44:1885-1893, 1979.
28. Oldfield EH, Ram Z, Chiang Y, Blaese RM: Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis: GTI0108-A phase I/II study. Hum Gene Ther 6:55-85, 1995.
29. Ongerboer de Visser BW, Somers R, Nooyen WH, Van Heerde P, Hart AA, McVie JG: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33:1565-1572, 1983.
30. Pizzo PA, Poplack DG, Bleyer WA: Neurotoxicities of current leukemia therapy. Am J Pediatr Hematol Oncol 1:127-140, 1979.
31. Price RA, Jamieson PA: The central nervous system in childhood leukemia: Part II-Subacute leukoencephalopathy. Cancer 35:306-318, 1975.
32. Rosen ST, Aisner J, Makuch RW, Matthews MJ, Ihde DC, Whitacre M, Glatstein EJ, Wiernik PH, Lichter AS, Bunn PA Jr: Carcinomatous leptomeningitis in small cell lung cancer: A clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore) 61:45-53, 1982.
33. Sause WT, Crowley J, Eyre HJ, Rivkin SE, Pugh RP, Quagliana JM, Taylor SA, Molnar B: Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases: A Southwest Oncology Group Study. J Neurooncol 6:107-112, 1988.
34. Shapiro WR, Posner JB, Ushio Y, Chernik NL, Young DF: Treatment of meningeal neoplasms. Cancer Treat Rep 61:733-743, 1977.
35. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumor: Experience with 90 patients. Cancer 49:759-772, 1982.
36. Yamada M, Nakagawa H, Fukushima M, Shimizu K, Hayakawa T, Ikenaka K: In vitro study on intrathecal use of 5-fluoro-2′-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors. J Neurooncol 37:115-121, 1998.